Priomed Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
- Paid Up Capital ₹ 0.12 M
- Company Age 10 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 33.61%
- Profit Growth 119.73%
- Ebitda 130.56%
- Net Worth 18.67%
- Total Assets 71.08%
About Priomed Life Sciences
Priomed Life Sciences Private Limited (PLSPL) is a Private Limited Indian Non-Government Company incorporated in India on 06 January 2015 and has a history of Ten years and one month. Its registered office is in Kanchipuram, Tamil Nadu, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.12 M, as per Ministry of Corporate Affairs (MCA) records.
Ganapathy Girirajan, Abdulhameed Ismail, and Ansar Basha serve as directors at the Company.
Company Details
-
Location
Kanchipuram, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74900TN2015PTC098727
-
Company No.
098727
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
06 Jan 2015
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Priomed Life Sciences?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ansar Basha
|
Director | 06-Jan-2015 | Current |
|
Abdulhameed Ismail
|
Director | 27-Sep-2016 | Current |
|
Ganapathy Girirajan
|
Director | 06-Jan-2015 | Current |
Financial Performance of Priomed Life Sciences.
Priomed Life Sciences Private Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 33.61% increase. The company also saw a substantial improvement in profitability, with a 119.73% increase in profit. The company's net worth Soared by an impressive increase of 18.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Priomed Life Sciences?
In 2017, Priomed Life Sciences had a promoter holding of 75.00% and a public holding of 25.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Priomed Life Sciences?
Unlock and access historical data on people associated with Priomed Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Priomed Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Priomed Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
